跳至主要内容
临床试验/NCT07201649
NCT07201649招募中不适用

Roles of Hepatic Insufficiency, Hepatic Fibrosis, and Inorganic Pyrophosphate in the Progression of Arterial Calcifications

Centre Hospitalier Universitaire de Nice2 个研究点 分布在 1 个国家目标入组 95 人开始时间: 2025年11月24日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
95
试验地点
2
主要终点
hepatic transplantation reduces arterial calcification

研究概览

简要总结

Individuals with metabolic syndrome (MetS), particularly those with type 2 diabetes (T2D), and/or metabolic dysfunction-associated steatohepatitis or MASH face an elevated risk of major cardiovascular events (MACE). We showed decrease plams level of PPi in patients with liver cirrhosis. We hypothezised that liver transplant should block AC and restore PPi plasma level.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • everyone requiring liver transplantation for the treatment of a chronic liver disease

排除标准

  • MELD score >25, viral replication

结局指标

主要结局

hepatic transplantation reduces arterial calcification

时间窗: On the 7th day after surgery

compare the percent of patients with AC progression before and after liver tranplantation

次要结局

  • increase of PPi plasma level after liver transplantation(at inclusion and at 3 months)
  • identify arterial calcification related factors(On the 7th day after surgery)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验